Cellular and molecular evidence for malignancyinhibitory functions of p15RS

Cell Cycle

Volumn 11, Issue 10, 2012, Pages 1988-1998

  Zhang, Xiaocui ^a   Cao, Qiuju ^a   Liu, Xiaodan ^a   Liu, Shuaishuai ^a   Wang, Juan ^a   Sun, Sheng ^a   Wang, Ou ^a   Tian, Zhihua ^b   Liu, Huitu ^a   Kuang, Jian ^c   Zhang, Wei ^a  

^a BEIJING NORMAL UNIVERSITY   (China)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anchorage independent cell growth; Cathepsin B; Cell migration and invasion; MMP 9; p15RS

Indexed keywords

AGAR; CATHEPSIN B; GELATINASE B; MATRIX PROTEIN; NUCLEAR PROTEIN; PROTEIN P15 RELATED SEQUENCE; RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL INVASION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MONOLAYER CULTURE; PROTEIN EXPRESSION;

EID: 84861372957     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.20400     Document Type: Article

References (99)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70; PMID:10647931; http:// dx.doi.org/10.1016/S0092-8674(00)81683-9.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j. cell.2011.02.013.
3. Vainio P, Lehtinen L, Mirtti T, Hilvo M, Seppänen- Laakso T, Virtanen J, et al. Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. Oncotarget 2011; 2:1176-90; PMID:22202492.
4. Weber GL, Parat MO, Binder ZA, Gallia GL, Riggins GJ. Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration and invasion in glioblastoma multiforme cells. Oncotarget 2011; 2:833-49; PMID:22064833.
5. Taraboletti G, Rusnati M, Ragona L, Colombo G. Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget 2010; 1:662-73; PMID:21317461.
6. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366:704-7; PMID:8259215; http://dx.doi.org/10.1038/366704a0.
7. Jeffrey PD, Tong L, Pavletich NP. Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors. Genes Dev 2000; 14:3115-25; PMID:11124804; http://dx.doi.org/10.1101/gad.851100.
8. Hirai H, Roussel MF, Kato JY, Ashmun RA, Sherr CJ. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 1995; 15:2672-81; PMID:7739547.
9. Chow KN, Starostik P, Dean DC. The Rb family contains a conserved cyclin-dependent-kinase-regulated transcriptional repressor motif. Mol Cell Biol 1996; 16:7173-81; PMID:8943373.
10. Mayol X, Garriga J, Graña X. Cell cycle-dependent phosphorylation of the retinoblastoma-related protein p130. Oncogene 1995; 11:801-8; PMID:7651744.
11. INK4, the product of the putative tumor suppressor gene MTS1. Oncogene 1994; 9:3475-82; PMID:7970707.
12. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, et al. Retinoblastoma-protein-dependent cell cycle inhibition by the tumour suppressor p16. Nature 1995; 375:503-6; PMID:7777060; http:// dx.doi.org/10.1038/375503a0.
13. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264:436-40; PMID:8153634; http:// dx.doi.org/10.1126/science. 8153634.
14. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1994; 265:415- 7; PMID:8023167; http://dx.doi.org/10.1126/science. 8023167.
15. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368:753-6; PMID:8152487; http:// dx.doi.org/10.1038/368753a0.
16. Ink4a. Nature 2007; 448:943-6; PMID:17713536; http://dx.doi. org/10.1038/nature06084.
17. INK4A transcript. Cancer Res 1995; 55:2995-7; PMID:7541708.
18. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARFINK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92:725-34; PMID:9529249; http://dx.doi.org/10. 1016/S0092- 8674(00)81401-4.
19. ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 2000; 19:2312- 23; PMID:10822382; http://dx.doi.org/10.1038/ sj.onc.1203593.
20. Chin L, Pomerantz J, DePinho RA. The INK4a/ ARF tumor suppressor: one gene - two products - two pathways. Trends Biochem Sci 1998; 23:291-6; PMID:9757829; http://dx.doi.org/10.1016/S0968- 0004(98)01236-5.
21. 1/S progression. Biochem Biophys Res Commun 2002; 299:880-5; PMID:12470661; http://dx.doi.org/10.1016/S0006-291X(02)02684-0.
22. INK4/MTS1, p18 and p19 in human cancer cell lines. Int J Cancer 1996; 68:605- 11; PMID:8938142; http://dx.doi.org/10. 1002/ (SICI)1097-0215(19961127)68:5〈605::AIDIJC9〉3.0.CO;2-2.
23. Wu Y, Zhang Y, Zhang H, Yang X, Wang Y, Ren F, et al. p15RS attenuates Wnt/beta-catenin signaling by disrupting beta-catenin•TCF4 Interaction. J Biol Chem 2010; 285:34621-31; PMID:20739273; http://dx.doi. org/10.1074/jbc. M110.148791.
24. Nakai M, Mundy GR, Williams PJ, Boyce B, Yoneda T. A synthetic antagonist to laminin inhibits the formation of osteolytic metastases by human melanoma cells in nude mice. Cancer Res 1992; 52:5395-9; PMID:1394144.
25. Shin SI, Freedman VH, Risser R, Pollack R. Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci USA 1975; 72:4435-9; PMID:172908; http://dx.doi.org/10.1073/ pnas.72.11.4435.
26. Colburn NH, Bruegge WF, Bates JR, Gray RH, Rossen JD, Kelsey WH, et al. Correlation of anchorageindependent growth with tumorigenicity of chemically transformed mouse epidermal cells. Cancer Res 1978; 38:624-34; PMID:626967.
27. Mort JS, Buttle DJ. Cathepsin B. Int J Biochem Cell Biol 1997; 29:715-20; PMID:9251238; http://dx.doi. org/10.1016/S1357-2725(96)00152-5.
28. Buck MR, Karustis DG, Day NA, Honn KV, Sloane BF. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J 1992; 282:273-8; PMID:1540143.
29. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003; 253:269-85; PMID:14619979; http://dx.doi. org/10.1023/A:1026028303196.
30. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 2012; 1825:29-36; PMID:22020293.
31. Nowicki TS, Zhao H, Darzynkiewicz Z, Moscatello A, Shin E, Schantz S, et al. Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/ Akt signaling and induces senescence in papillary thyroid carcinoma cells. Cell Cycle 2011; 10:100- 7; PMID:21191179; http://dx.doi.org/10.4161/ cc.10.1.14362.
32. Kunigal S, Lakka SS, Gondi CS, Estes N, Rao JS. RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease- 9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int J Cancer 2007; 121:2307-16; PMID:17657740; http://dx.doi. org/10.1002/ijc.22962.
33. Lakka SS, Gondi CS, Dinh DH, Olivero WC, Gujrati M, Rao VH, et al. Specific interference of urokinasetype plasminogen activator receptor and matrix metalloproteinase- 9 gene expression induced by doublestranded RNA results in decreased invasion, tumor growth and angiogenesis in gliomas. J Biol Chem 2005; 280:21882-92; PMID:15824107; http://dx.doi. org/10.1074/jbc.M408520200.
34. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005; 8:179-83; PMID:16169463; http://dx.doi.org/10.1016/j.ccr.2005.08.008.
35. Dobashi Y, Watanabe Y, Miwa C, Suzuki S, Koyama S. Mammalian target of rapamycin: a central node of complex signaling cascades. Int J Clin Exp Pathol 2011; 4:476-95; PMID:21738819.
36. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 2004; 91:1420-4; PMID:15365568; http:// dx.doi.org/10.1038/sj.bjc.6602162.
37. Howe A, Aplin AE, Alahari SK, Juliano RL. Integrin signaling and cell growth control. Curr Opin Cell Biol 1998; 10:220-31; PMID:9561846; http://dx.doi. org/10.1016/S0955-0674(98)80144-0.
38. Clark EA, Brugge JS. Integrins and signal transduction pathways: the road taken. Science 1995; 268:233- 9; PMID:7716514; http://dx.doi.org/10.1126/ science. 7716514.
39. Cary LA, Han DC, Guan JL. Integrin-mediated signal transduction pathways. Histol Histopathol 1999; 14:1001-9; PMID:10425567.
40. Siesser PM, Hanks SK. The signaling and biological implications of FAK overexpression in cancer. Clin Cancer Res 2006; 12:3233-7; PMID:16740741; http://dx.doi.org/10.1158/1078-0432.CCR-06-0456.
41. Bianchi A, Gervasi ME, Bakin A. Role of β5-integrin in epithelial-mesenchymal transition in response to TGFβ. Cell Cycle 2010; 9:1647-59; PMID:20404485; http://dx.doi.org/10.4161/cc.9.8.11517.
42. Hall A. The cellular functions of small GTP-binding proteins. Science 1990; 249:635-40; PMID:2116664; http://dx.doi.org/10.1126/science.2116664.
43. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002; 420:629-35; PMID:12478284; http://dx.doi.org/10.1038/nature01148.
44. Narumiya S, Tanji M, Ishizaki T. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev 2009; 28:65-76; PMID:19160018; http://dx.doi.org/10.1007/s10555- 008-9170-7.
45. Jaffe AB, Hall A. Rho GTPases in transformation and metastasis. Adv Cancer Res 2002; 84:57-80; PMID:11883532; http://dx.doi.org/10.1016/S0065- 230X(02)84003-9.
46. Vega FM, Ridley AJ. Rho GTPases in cancer cell biology. FEBS Lett 2008; 582:2093-101; PMID:18460342; http://dx.doi.org/10.1016/j.febslet.2008.04.039.
47. Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev 2004; 18:862- 76; PMID:15078817; http://dx.doi.org/10. 1101/gad.1185504.
48. Kip1 phosphorylation. Cell Cycle 2010; 9:2057-8; PMID:20505330; http://dx.doi.org/10.4161/cc.9.11.11927.
49. Nagano Y, Fukushima T, Okemoto K, Tanaka K, Bowtell DD, Ronai Z, et al. Siah1/SIP regulates p27(kip1) stability and cell migration under metabolic stress. Cell Cycle 2011; 10:2592-602; PMID:21734459; http:// dx.doi.org/10.4161/cc.10.15.16912.
50. See WL, Heinberg AR, Holland EC, Resh MD. p27 deficiency is associated with migration defects in PDGF-expressing gliomas in vivo. Cell Cycle 2010; 9:1562-7; PMID:20404478; http://dx.doi. org/10.4161/cc.9.8.11259.
51. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev 2007; 17:45-51; PMID:17208432; http:// dx.doi.org/10.1016/j.gde.2006.12.007.
52. Grigoryan T, Wend P, Klaus A, Birchmeier W. Deciphering the function of canonical Wnt signals in development and disease: conditional loss- and gain-offunction mutations of beta-catenin in mice. Genes Dev 2008; 22:2308-41; PMID:18765787; http://dx.doi. org/10.1101/gad.1686208.
53. Bassères DS, Baldwin AS. Nuclear factorkappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006; 25:6817- 30; PMID:17072330; http://dx.doi.org/10.1038/ sj.onc.1209942.
54. Perkins ND. The diverse and complex roles of NFκB subunits in cancer. Nat Rev Cancer 2012; 12:121-32; PMID:22257950.
55. Hofmann UB, Becker JC, Bröcker EB. Role of matrixdegrading enzymes in melanoma progression. Hautarzt 2002; 53:587-95; PMID:12207262; http://dx.doi.org/10.1007/s00105-001-0301-0.
56. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS. RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 2004; 23:8486-96; PMID:15378018; http://dx.doi. org/10.1038/sj.onc.1207879.
57. Becker R, Loll B, Meinhart A. Snapshots of the RNA processing factor SCAF8 bound to different phosphorylated forms of the carboxyl-terminal domain of RNA polymerase II. J Biol Chem 2008; 283:22659- 69; PMID:18550522; http://dx.doi.org/10.1074/jbc. M803540200.
58. Pei Y, Hausmann S, Ho CK, Schwer B, Shuman S. The length, phosphorylation state and primary structure of the RNA polymerase II carboxyl-terminal domain dictate interactions with mRNA capping enzymes. J Biol Chem 2001; 276:28075-82; PMID:11387325; http:// dx.doi.org/10.1074/jbc.M102170200.
59. Wu B, Crampton SP, Hughes CC. Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. Immunity 2007; 26:227- 39; PMID:17306568; http://dx.doi.org/10.1016/j. immuni.2006.12.007.
60. Yan S, Berquin IM, Troen BR, Sloane BF. Transcription of human cathepsin B is mediated by Sp1 and Ets family factors in glioma. DNA Cell Biol 2000; 19:79-91; PMID:10701774; http://dx.doi. org/10.1089/104454900314591.
61. Westermarck J, Kähäri VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999; 13:781-92; PMID:10224222.
62. Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, Kramer M, et al. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J Biol Chem 1991; 266:5147-52; PMID:1900515.
63. Guo M, Mathieu PA, Linebaugh B, Sloane BF, Reiners JJ Jr. Phorbol ester activation of a proteolytic cascade capable of activating latent transforming growth factor-betaL a process initiated by the exocytosis of cathepsin B. J Biol Chem 2002; 277:14829-37; PMID:11815600; http://dx.doi.org/10.1074/jbc. M108180200.
64. Qian F, Bajkowski AS, Steiner DF, Chan SJ, Frankfater A. Expression of five cathepsins in murine melanomas of varying metastatic potential and normal tissues. Cancer Res 1989; 49:4870-5; PMID:2758418.
65. Fröhlich E, Schlagenhauff B, Möhrle M, Weber E, Klessen C, Rassner G. Activity, expression and transcription rate of the cathepsins B, D, H and L in cutaneous malignant melanoma. Cancer 2001; 91:972-82; PMID:11251949; http://dx.doi. org/10.1002/1097-0142(20010301)91:5〈972::AIDCNCR1087〉3. 0.CO;2-Q.
66. Poole AR, Tiltman KJ, Recklies AD, Stoker TA. Differences in secretion of the proteinase cathepsin B at the edges of human breast carcinomas and fibroadenomas. Nature 1978; 273:545-7; PMID:661963; http:// dx.doi.org/10.1038/ 273545a0.
67. Maguire TM, Shering SG, Duggan CM, McDermott EW, O'Higgins NJ, Duffy MJ. High levels of cathepsin B predict poor outcome in patients with breast cancer. Int J Biol Markers 1998; 13:139-44; PMID:10079387.
68. Lah TT, Kokalj-Kunovar M, Drobnic-Kosorok M, Babnik J, Golouh R, Vrhovec I, et al. Cystatins and cathepsins in breast carcinoma. Biol Chem Hoppe Seyler 1992; 373:595-604; PMID:1515089; http:// dx.doi.org/10.1515/bchm3.1992.373.2. 595.
69. Bervar A, Zajc I, Sever N, Katunuma N, Sloane BF, Lah TT. Invasiveness of transformed human breast epithelial cell lines is related to cathepsin B and inhibited by cysteine proteinase inhibitors. Biol Chem 2003; 384:447-55; PMID:12715895; http://dx.doi. org/10.1515/BC.2003.050.
70. Krepela E, Kasafírek E, Novák K, Viklický J. Increased cathepsin B activity in human lung tumors. Neoplasma 1990; 37:61-70; PMID:2320181.
71. Kobayashi H, Ohi H, Sugimura M, Shinohara H, Fujii T, Terao T. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res 1992; 52:3610- 4; PMID:1617632.
72. Mohanam S, Jasti SL, Kondraganti SR, Chandrasekar N, Lakka SS, Kin Y, et al. Downregulation of cathepsin B expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene 2001; 20:3665-73; PMID:11439329; http://dx.doi. org/10.1038/sj.onc.1204480.
73. Konduri S, Lakka SS, Tasiou A, Yanamandra N, Gondi CS, Dinh DH, et al. Elevated levels of cathepsin B in human glioblastoma cell lines. Int J Oncol 2001; 19:519-24; PMID:11494030.
74. Hughes SJ, Glover TW, Zhu XX, Kuick R, Thoraval D, Orringer MB, et al. A novel amplicon at 8p22-23 results in overexpression of cathepsin B in esophageal adenocarcinoma. Proc Natl Acad Sci USA 1998; 95:12410-5; PMID:9770500; http://dx.doi. org/10.1073/pnas.95.21.12410.
75. Brix K, Dunkhorst A, Mayer K, Jordans S. Cysteine cathepsins: cellular roadmap to different functions. Biochimie 2008; 90:194-207; PMID:17825974; http://dx.doi.org/10.1016/j.biochi.2007.07.024.
76. Sopata I, Wize J. A latent gelatin specific proteinase of human leucocytes and its activation. Biochim Biophys Acta 1979; 571:305-12; PMID:508769.
77. Vartio T, Hovi T, Vaheri A. Human macrophages synthesize and secrete a major 95,000-dalton gelatinbinding protein distinct from fibronectin. J Biol Chem 1982; 257:8862-6; PMID:7047529.
78. Redondo-Muñoz J, Ugarte-Berzal E, García-Marco JA, del Cerro MH, Van den Steen PE, Opdenakker G, et al. Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/ MMP-9 in chronic leukemic but not in normal B cells. Blood 2008; 112:169-78; PMID:18326820; http:// dx.doi.org/10.1182/blood-2007-08-109249.
79. Takino T, Koshikawa N, Miyamori H, Tanaka M, Sasaki T, Okada Y, et al. Cleavage of metastasis suppressor gene product KiSS-1 protein/metastin by matrix metalloproteinases. Oncogene 2003; 22:4617- 26; PMID:12879005; http://dx.doi.org/10.1038/ sj.onc.1206542.
80. Mendes O, Kim HT, Stoica G. Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin Exp Metastasis 2005; 22:237-46; PMID:16158251; http://dx.doi.org/10.1007/s10585- 005-8115-6.
81. Somiari SB, Somiari RI, Heckman CM, Olsen CH, Jordan RM, Russell SJ, et al. Circulating MMP2 and MMP9 in breast cancer - potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer 2006; 119:1403- 11; PMID:16615109; http://dx.doi.org/10.1002/ ijc.21989.
82. Lakka SS, Gondi CS, Yanamandra N, Olivero WC, Dinh DH, Gujrati M, et al. Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 2004; 23:4681-9; PMID:15122332; http://dx.doi. org/10.1038/sj.onc. 1207616.
83. Zhang W, Yang HC, Wang Q, Yang ZJ, Chen H, Wang SM, et al. Clinical value of combined detection of serum matrix metalloproteinase-9, heparanase and cathepsin for determining ovarian cancer invasion and metastasis. Anticancer Res 2011; 31:3423-8; PMID:21965756.
84. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2:737-44; PMID:11025665; http://dx.doi. org/10.1038/35036374.
85. Zeng ZS, Guillem JG. Unique activation of matrix metalloproteinase-9 within human liver metastasis from colorectal cancer. Br J Cancer 1998; 78:349- 53; PMID:9703281; http://dx.doi.org/10.1038/ bjc.1998.497.
86. Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, et al. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 1993; 53:5365-9; PMID:8221672.
87. Miyamoto H, Altuwaijri S, Cai Y, Messing EM, Chang C. Inhibition of the Akt, cyclooxygenase-2 and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer. Mol Carcinog 2005; 44:1-10; PMID:16044418; http://dx.doi.org/10.1002/ mc.20121.
88. Cox G, Jones JL, O'Byrne KJ. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 2000; 6:2349-55; PMID:10873086.
89. MacDougall JR, Bani MR, Lin Y, Rak J, Kerbel RS. The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells. Cancer Res 1995; 55:4174-81; PMID:7664294.
90. Trojanowska M. Ets factors and regulation of the extracellular matrix. Oncogene 2000; 19:6464- 71; PMID:11175362; http://dx.doi.org/10.1038/ sj.onc.1204043.
91. Owen JL, Torroella-Kouri M, Iragavarapu-Charyulu V. Molecular events involved in the increased expression of matrix metalloproteinase-9 by T lymphocytes of mammary tumor-bearing mice. Int J Mol Med 2008; 21:125-34; PMID:18097625.
92. INK4c in tumor-derived cell lines and primary tumors. Oncogene 1996; 12:451-5; PMID:8570224.
93. INK4 gene) during tumor progression in a sporadic melanoma patient. Cancer Res 1995; 55:5531-5; PMID:7585628.
94. Ink4bresults in monocytosis and predisposition to myeloid leukemia. Blood 2010; 116:979-87; PMID:20457873; http://dx.doi.org/10.1182/blood-2009-08-238360.
95. Xu H, Zhou YL, Zhang XY, Lu P, Li GS. Activation of PERK signaling through fluoride-mediated endoplasmic reticulum stress in OS732 cells. Toxicology 2010; 277:1-5; PMID:20709135; http://dx.doi. org/10.1016/j.tox.2010. 08.006.
96. Zhou L, Picard D, Ra YS, Li M, Northcott PA, Hu Y, et al. Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma. Cancer Res 2010; 70:8199-210; PMID:20876797; http://dx.doi.org/10.1158/0008-5472.CAN-09-4562.
97. Tian T, Hao J, Xu A, Hao J, Luo C, Liu C, et al. Determination of metastasis-associated proteins in non-small cell lung cancer by comparative proteomic analysis. Cancer Sci 2007; 98:1265-74; PMID:17537172; http://dx.doi.org/10.1111/j.1349-7006.2007.00514.x.
98. Veeravalli KK, Chetty C, Ponnala S, Gondi CS, Lakka SS, Fassett D, et al. MMP-9, uPAR and cathepsin B silencing downregulate integrins in human glioma xenograft cells in vitro and in vivo in nude mice. PLoS One 2010; 5:11583; PMID:20657647; http://dx.doi. org/10.1371/journal.pone.0011583.
99. Mitra RS, Goto M, Lee JS, Maldonado D, Taylor JM, Pan Q, et al. Rap1GAP promotes invasion via induction of matrix metalloproteinase 9 secretion, which is associated with poor survival in low N-stage squamous cell carcinoma. Cancer Res 2008; 68:3959-69; PMID:18483282; http://dx.doi.org/10.1158/0008-5472.CAN-07- 2755.